Abstract PO-170: Association between outdoor ambient benzene and invasive breast cancer incidence: The Multiethnic Cohort Study

Author(s):  
Ugonna Ihenacho ◽  
Jun Wu ◽  
Chiu-Chen Tseng ◽  
Juan Yang ◽  
Scott Fruin ◽  
...  
2020 ◽  
Author(s):  
Anna H. Wu ◽  
Adrian A. Franke ◽  
Chiuchen Tseng ◽  
Shannon M. Conroy ◽  
Yuqing S. LI ◽  
...  

2019 ◽  
Vol 146 (3) ◽  
pp. 664-670 ◽  
Author(s):  
Maryssa Shigesato ◽  
Yosuke Kawai ◽  
Cherie Guillermo ◽  
Fadi Youkhana ◽  
Yurii B. Shvetsov ◽  
...  

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 25-25
Author(s):  
Nananda Col ◽  
Leslie Ochs ◽  
Vicky Springmann ◽  
Aaron K Aragaki ◽  
Rowan T. Chlebowski

25 Background: Observational studies have suggested that metformin, commonly used for diabetes treatment that increases insulin sensitivity and improves glycemic control, decreases the incidence of several common cancers. However, findings regarding metformin and breast cancer incidence have been mixed. To explore this issue, a systematic literature review and meta-analysis were performed with a focus on potential biases. Methods: We conducted a comprehensive literature search for all pertinent studies addressing metformin use and breast cancer risk by searching Pub Med, Cochrane Library, Scopus (which includes Embase, ISI Web of Science) using the Mesh terms: "metformin" or "biguanides" or "diabetes mellitus, type 2/therapy" and "cancer" or "neoplasms". When multiple hazard ratios (HR) or odds ratio (OR) were reported, the most adjusted estimate was used in the base-case analysis. We pooled the adjusted HR using and performed sensitivity analyses on duration of metformin use (> or < 3 years use), study quality (assessed using the GRADE system), and initial observation year of the cohort (before vs after 1997). Results: From a total of 421 citations, 13 full-text articles were considered, and 7 independent studies were included. All were observational (4 cohort and 3 case control). Our combined OR for metformin association with invasive breast cancer of all 7 studies was 0.83 (95% CI, 0.71-0.97). Funnel plot analyses did not suggest publication bias. Stronger associations were found when analyses were limited to studies estimating the impact of longer metformin duration (OR = 0.75. 95% CI, 0.62-0.91) or among studies that began observing their cohort before 1997 (OR=0.68. 95% CI, 0.55-0.84). Stratification according to study quality did not affect the combined OR but higher quality studies had smaller CI and achieved statistical significance. Interpretation is limited by the observational nature of reports and different comparison groups. Conclusions: Our analyses support a protective effect of metformin on invasive breast cancer incidence among postmenopausal women with diabetes. Clinical trials are needed to determine whether metformin reduces breast cancer risk.


2016 ◽  
Vol 26 (3) ◽  
pp. 428-430 ◽  
Author(s):  
Zorana Jovanovic Andersen ◽  
Line Ravnskjær ◽  
Klaus Kaae Andersen ◽  
Steffen Loft ◽  
Jørgen Brandt ◽  
...  

The Lancet ◽  
2014 ◽  
Vol 384 ◽  
pp. S53 ◽  
Author(s):  
Michelle A Morris ◽  
Claire Hulme ◽  
Graham P Clarke ◽  
Kimberley L Edwards ◽  
Janet E Cade

Sign in / Sign up

Export Citation Format

Share Document